Monday, August 28, 2023
Sandoz, a major player in the field of generic and biosimilar medicines, has successfully concluded the acquisition of the global brand rights for Mycamine® (micafungin sodium), a leading systemic antifungal agent. This acquisition was made from Astellas.
By securing the rights to this prominent echinocandin, one of the primary antifungal classes globally, Sandoz significantly enhances its global hospital offerings and strengthens its portfolio of advanced anti-infective medications.
In the financial year ending on March 31, 2023, Astellas reported sales of Mycamine® totaling JPY 14.2 billion (USD 105 million). This acquisition follows Sandoz's previous successful acquisition of GSK's global cephalosporins portfolio in October 2021.
Richard Saynor, the CEO of Sandoz, stated, "This move underscores our steadfast commitment at Sandoz to facilitate responsible access to vital antimicrobial drugs. We're not only investing in our manufacturing network but also thoughtfully expanding our premier portfolio in this sector. This ensures that we can consistently provide the right medication to patients worldwide, at the right time."
With a global user base exceeding two million, Mycamine® is a preferred therapy in hospitals and intensive care units worldwide. It has proven to be an effective prophylactic option for patients in hematology and oncology and is extensively used in organ transplant procedures.
Mycamine® is indicated for the treatment of invasive candidiasis and esophageal candidiasis, both of which are currently on the rise and often linked with outbreaks in hospital settings. Moreover, it is employed for the prevention of candida and aspergillus infections in patients undergoing hematopoietic stem cell transplantation.
